Sugi Predict

Sugi Predict / Compounds / SCHEMBL30980633

SCHEMBL30980633

SCHEMBL30980633

CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1c1ccn(CCOCCOCCNC(=O)NCCCC(N)(CCCNC(=O)NCCOCCOCCn2ccc([C@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)n2)CCCNC(=O)NCCOCCOCCn2ccc([C@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)n2)n1

nearest known ligand 0.38

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 2/20 0.38
▸ OGA O60502 8/20 0.37
▸ HEXB P07686 6/20 0.36
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 2/20 0.34
▸ CA9 Q16790 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ SLC9A3 P48764 2/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980768 0.89 LGALS3 (0.35) LGALS3OGAHEXB
SCHEMBL30980689 0.84 LGALS3 (0.41) LGALS3CA1CA2CA9MAPK1
SCHEMBL30980722 0.78 OGA (0.35) LGALS3OGACA1CA2CA9
SCHEMBL30980709 0.77 MAPK1 (0.41) LGALS3OGAHEXBMAPK1
SCHEMBL30980721 0.71 LGALS3 (0.49) LGALS3CA1CA2CA9MAPK1
SCHEMBL30980552 0.70 LGALS3 (0.54) LGALS3OGACA1CA2CA9
SCHEMBL30980522 0.69 MAPK1 (0.43) LGALS3OGAHEXBCA1CA2
SCHEMBL30980568 0.67 MAPK1 (0.38) LGALS3OGAHEXBMAPK1
SCHEMBL30980642 0.66 MAPK1 (0.43) LGALS3CA1CA2CA9MAPK1
SCHEMBL18972884 0.66 MAPK1 (0.53) LGALS3CA1CA2CA9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
EP-4651901-A1 CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 — — WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
Send feedback